Fluxus
Private Company
Total funding raised: $3.2M
Overview
Fluxus is a San Francisco-based innovator in ultrasensitive bioanalysis, operating at the intersection of optofluidics, microengineering, and assay development. Its core technology platform is designed for single-molecule counting, targeting a significant gap in clinical research and diagnostics by enabling highly sensitive detection of any analyte in any setting. Acquired by Fujirebio Holdings in 2022, the company now blends Silicon Valley agility with the resources of a multinational corporation to commercialize its detection systems and assay solutions.
Technology Platform
Optofluidic platform combining advanced photonics and microfluidics for ultrasensitive, single-molecule detection of a wide range of biomolecular targets in configurable formats.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Fluxus competes in the ultrasensitive bioanalysis market against established players like Quanterix (Simoa technology) and Meso Scale Diagnostics, as well as other companies developing digital ELISA and single-molecule detection methods. Its differentiation hinges on the specific performance, flexibility, and cost profile of its optofluidic platform.